WorkBoat Header Background Image

WorkBoat+ Membership – Free to Join

Now Available: The U.S. Dredge Report 2025 — download today for expert dredging market insights and data → Click Here

Workboat Indexes

Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Workboat Indexes
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Caribou Biosciences, Inc. - Common Stock (NQ:CRBU)

1.900 +0.180 (+10.47%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Caribou Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences to Participate in Upcoming Investor Conferences
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences Announces Late-Breaking Presentations at the 2026 Tandem Meetings of ASTCT® and CIBMTR®
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge
Issued on behalf of GT Biopharma, Inc. 
From Equity Insider
Via GlobeNewswire
News headline image
Caribou Biosciences to Host In-Person and Virtual KOL Event at ASH 2025
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences to Participate in Upcoming Investor Conferences
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Aprea Therapeutics (Nasdaq: APRE) Transforms Cutting-Edge Science into Next-Generation Cancer Therapies – More Stocks Inside
Via AB Newswire
Topics Artificial Intelligence
News headline image
Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010), an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences to Participate in the Citi 2025 Biopharma Back to School Conference
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
CARIBOU ALERT: Bragar Eagel & Squire, P.C. is Investigating Caribou Biosciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Caribou Biosciences to Participate in the Jefferies Global Healthcare Conference
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences Reports First Quarter 2025 Financial Results and Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences to Participate in the BofA Securities 2025 Health Care Conference
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
CARIBOU ALERT: Bragar Eagel & Squire, P.C. is Investigating Caribou Biosciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
CRBU DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important February 24 Deadline in Securities Class Action - CRBU
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Caribou Biosciences to Participate in Upcoming Investor Conferences
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
CRBU Deadline: Rosen Law Firm Urges Caribou Biosciences, Inc. (NASDAQ: CRBU) Investors to Contact the Firm for Information About Their Rights
From Rosen Law Firm
Via Business Wire
News headline image
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Capri, Caribou, BioAge, and Transocean and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
ROSEN, A LEADING NATIONAL FIRM, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CRBU
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Capri, Caribou, Nextracker, and Transocean and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CRBU
From The Rosen Law Firm PA
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Privacy Policy DSAR Requests Terms of Use Locations Events, Products & Services
© 2026 Diversified Communications. All rights reserved.